Related Experiment Video
Updated: Apr 26, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the
Amir Azarbal1, Leonardo Clavijo2, Michael A Gaglia3
1Department of Internal Medicine, University of Alabama-Huntsville, Huntsville, AL, USA.
Insights
Antiplatelet therapy is standard for peripheral arterial disease but lacks strong evidence in this high-risk group. Current treatments show limited effectiveness for peripheral vascular outcomes.
Area of Science:
- Vascular Medicine
- Pharmacology
- Clinical Guidelines
Background:
- Antiplatelet therapy is a cornerstone in managing peripheral arterial disease (PAD) and critical limb ischemia (CLI).
- Major society guidelines recommend antiplatelet agents for these high-risk patients.
- However, robust clinical trial data supporting these recommendations in PAD/CLI populations is often limited.
Purpose of the Study:
- To summarize current guidelines on antiplatelet therapy for PAD and CLI.
- To review existing studies on antiplatelet agents in PAD.
- To provide perspective on newer agents and discuss overall efficacy.
Main Methods:
- Systematic review of major guidelines for antiplatelet therapy in PAD/CLI.
- Comprehensive literature search of clinical trials evaluating aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids in PAD.
- Analysis of data on newer agents like ticagrelor, vorapaxar, and rivaroxaban.
Main Results:
- Guidelines consistently recommend antiplatelet therapy for PAD and CLI.
- Evidence for established agents like aspirin and clopidogrel in PAD shows variable results.
- Data on newer agents is emerging, but definitive efficacy in peripheral vascular outcomes remains uncertain.
Conclusions:
- Despite guideline recommendations, high-quality evidence for antiplatelet therapy in PAD/CLI is scarce.
- Established antiplatelet agents demonstrate a relative lack of efficacy for peripheral vascular outcomes.
- Further research is needed to clarify the role and optimal use of antiplatelet therapy in PAD and CLI.
Abstract:
Antiplatelet therapy is invariably prescribed for patients with peripheral arterial disease and critical limb ischemia, and numerous major society guidelines espouse their use, but high-quality data in this high-risk and challenging patient population are often lacking. This article summarizes the major guidelines for antiplatelet therapy, reviews the major studies of antiplatelet therapy in peripheral arterial disease (including data for aspirin, clopidogrel, dipyridamole, cilostazol, and prostanoids), and offers perspective on the potential benefits of ticagrelor, vorapaxar, and rivaroxaban. The review concludes with a discussion of the relative lack of efficacy that antiplatelet therapy has shown in regard to peripheral vascular outcomes.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease IV: Nursing Management